Current location - Health Preservation Learning Network - Slimming men and women - Kangmei Pharmaceutical filed for bankruptcy and reorganization, and the risk of delisting was highlighted?
Kangmei Pharmaceutical filed for bankruptcy and reorganization, and the risk of delisting was highlighted?
Yes, in September 2020, *ST Kangmei announced that the controlling shareholder and actual controller of the company planned to change to Yilin Investment. After further infiltration, the actual controllers of the three shareholders of Yilin Investment are all state-owned. Although it was taken over by state-owned assets, at present *ST Kangmei is still in deep crisis.

By the end of March, the company's total book assets were 3.6/kloc-0.20 billion yuan, total liabilities were 43.777 billion yuan, book monetary funds were only 5.8/kloc-0.00 billion yuan, and short-term loans, long-term loans and bonds payable totaled 2 1.732 billion yuan. ?

Due to the tight capital flow, *ST Kangmei failed to raise the payment funds for the 20 18 first-phase medium-term notes and other three-phase notes on schedule. At the same time, five other bills of the company triggered the early expiration of the cross-protection clause on April 25. At the same time, *ST Kangmei's investor litigation claim case is being tried through the special representative litigation procedure. ?

In addition, due to the negative audited net assets of *ST Kangmei at the end of 2020, the occupation of non-operating funds by related parties, and the inability to express opinions in the 2020 financial accounting report and the negative internal control audit report, the company's shares were given a delisting risk warning on April 29. ?

According to the rules of Shanghai Stock Exchange, if the audited net assets of *ST Kangmei are negative at the end of two consecutive years, or financial audit reports that cannot express opinions or negative opinions are issued for two consecutive years, the company's shares will be forcibly delisted. Judging from the data of a quarterly report, *ST Kangmei's time for "self-help" is running out. ?

Some institutional investors said that after the state-owned assets entered the company, the debt problem of Kangmei Pharmaceutical has not been substantially solved, and there is no news of official direct financial support. After entering the stage of bankruptcy reorganization, there is great uncertainty, and the trend after the intervention of state-owned assets is still unclear. At present, there is a risk of delisting, and investors are cautiously involved.

Kangmei Pharmaceutical was filed for bankruptcy and reorganization by creditors?

Recently, *ST Kangmei was applied for bankruptcy reorganization by Guangdong Jiedong Rural Commercial Bank Co., Ltd., with the case number of "Guangdong 52 Broken Application 1". Judging from the announcement of *ST Kangmei, as of April 22, the company has not repaid the loan principal of Jiedong Rural Commercial Bank of 49 million yuan and interest of about 500,000 yuan. ?

*ST Kangmei said that if the court formally accepts the company's reorganization application, the company will face the risk of being declared bankrupt due to the failure of reorganization. If the company is declared bankrupt, it will be liquidated. According to the listing rules of Shanghai Stock Exchange, the company's shares will also face the risk of being terminated.